The BAFF-APRIL System in Cancer

B cell-activating factor (BAFF; also known as CD257, TNFSF13B, BLyS) and a proliferation-inducing ligand (APRIL; also known as CD256, TNFSF13) belong to the tumor necrosis factor (TNF) family. BAFF was initially discovered as a B-cell survival factor, whereas APRIL was first identified as a protein highly expressed in various cancers. These discoveries were followed by over two decades of extensive research effort, which identified overlapping signaling cascades between BAFF and APRIL, controlling immune homeostasis in health and driving pathogenesis in autoimmunity and cancer, the latter being the focus of this review. High levels of BAFF, APRIL, and their receptors have been detected in different cancers and found to be associated with disease severity and treatment response. Here, we have summarized the role of the BAFF-APRIL system in immune cell differentiation and immune tolerance and detailed its pathogenic functions in hematological and solid cancers. We also highlight the emerging therapeutics targeting the BAFF-APRIL system in different cancer types.

Automated summary

B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) are members of the tumor necrosis factor (TNF) family, playing crucial roles in immune homeostasis and driving pathogenesis in autoimmunity and cancer. High levels of BAFF, APRIL, and their receptors are associated with disease severity and treatment response in different cancers. This review discusses the role of the BAFF-APRIL system in immune cell differentiation and tolerance, its pathogenic functions in hematological and solid cancers, and highlights emerging therapeutics targeting this system in various cancer types.